Aberrant ARMCX1 Expression Is an Independent Predictor of Poor Prognosis in Gastric Cancer

Table 2

Logistic regression of NUDT10 expression and clinicopathological parameters in TCGA and our validation cohort.

TCGA cohort		TN	OR	95% CI	value
Clinical features
Age	≥65 vs. <65	371	0.611	0.403-0.922	0.193
Gender	Female vs. male	375	0.946	0.620-1.444	0.799
Grade	G2 vs. G1	146	0.638	0.157-2.332	0.501
	G3 vs. G1	229	0.991	0.269-3.655	0.989
T stage	T2 vs. T1	99	7.216	2.191-32.814	0.003
	T3 vs. T1	187	6.154	1.961-27.163	0.005
	T4 vs. T1	119	24.857	4.839-455.953	0.002
LN metastasis	Yes vs. no	357	0.717	0.456-1.123	0.147
Distant metastasis	Yes vs. no	355	1.866	0.817-4.522	0.148
TNM stage	Stage II vs. stage I	164	2.088	1.076-4.129	0.031
	Stage III vs. stage I	203	2.409	1.267-4.706	0.008
	Stage IV vs. stage I	91	2.612	1.120-6.286	0.028
Validation cohort
Age	≥65 vs. <65	52	2.576	0.854-8.171	0.098
Gender	Female vs. male	52	1.437	0.441-4.837	0.549
Grade	G3 VS G1 + G2	52	0.858	0.285-2.554	0.781
Tumor size	≥5 cm vs. <5 cm	52	0.629	0.206-1.871	0.406
T stage	T4 VS T1 + T2 + T3	52	9.048	2.718-34.458	<0.001
LN metastasis	Yes vs. no	52	3.600	1.173-11.852	0.029
TNM stage	Stage III vs. stage I/II	52	3.600	1.173-11.852	0.029

Abbreviations: OR: odds ratio; TN: total number; CI, confidence interval; LN: lymph node. Italics indicate statistical significance of expression level with , , .